micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)	liposomal amphotericin B (3 mg/kg/day)	treatment success in ICU subjects	892	1052	for ICU subjects, treatment success rates for micafungin versus liposomal amphotericin B were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110); P = 0.5828)
micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)	liposomal amphotericin B (3 mg/kg/day)	treatment success in non-ICU subjects	21399	21569	In non-ICU subjects, the treatment success rate was significantly higher among subjects receiving micafungin than liposomal amphotericin B (85% versus 72.1%; P = 0.0113).
micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)	liposomal amphotericin B (3 mg/kg/day)	treatment success in ICU subjects	883	1053	However, for ICU subjects, treatment success rates for micafungin versus liposomal amphotericin B were similar (62.5% (n = 75/120) versus 66.4% (n = 73/110); P = 0.5828).
micafungin (100 mg/day for subjects > 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)	liposomal amphotericin B (3 mg/kg/day)	treatment success in non-ICU subjects	713	882	In non-ICU subjects, treatment success was significantly higher for micafungin versus liposomal amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/136); P = 0.0113).
micafungin (100 mg/day for subjects 40 kg; 2 mg/kg/day for subjects ≤ 40 kg)	liposomal amphotericin B (3 mg/kg/day)	renal function in ICU and non-ICU subjects	1817	2132	Renal function was significantly better in micafungin versus liposomal amphotericin B subjects: a difference (liposomal amphotericin B - micafungin in mean peak change in estimated glomerular filtration rate (ml/minute/1.73 m2) of -18.2 (P < 0.0001) and -17.7 (P = 0.0124) in non-ICU and ICU subjects, respectively.
